

Supp. Table 1 HPV-16 antibody responses up to Month 60 by age stratum and pre-vaccination serostatus (Month 60 ATP-I)

Age (years)	Pre-vaccination status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
9–25	Seronegative	0	127	0 (0.0)	4.0 (4.0, 4.0)	119	0 (0.0)	4.0 (4.0, 4.0)
		7	127	127 (100)	14891.7 (12363.5, 17936.8)	119	119 (100)	8854.4 (7569.7, 10357.2)
		12	126	126 (100)	5188.2 (4253.7, 6328.0)	119	119 (100)	2685.7 (2300.6, 3135.4)
		18	125	125 (100)	3421.2 (2820.6, 4149.8)	119	119 (100)	1826.6 (1560.0, 2138.9)
		24	125	125 (100)	2677.6 (2210.6, 3243.3)	118	118 (100)	1401.4 (1203.6, 1631.8)
		36	127	127 (100)	2265.4 (1883.9, 2724.0)	116	116 (100)	1176.1 (1004.7, 1376.8)
		48	122	122 (100)	1894.8 (1574.9, 2279.7)	118	118 (100)	1002.4 (857.7, 1171.5)
		60	127	127 (100)	1830.1 (1543.1, 2170.4)	119	119 (100)	992.0 (851.7, 1155.5)
	Seropositive	0	19	19 (100)	27.7 (14.9, 51.4)	12	12 (100)	38.1 (18.6, 77.9)
		7	19	19 (100)	11633.1 (6832.7, 19805.8)	12	12 (100)	5542.4 (3308.4, 9284.8)
		12	19	19 (100)	5268.7 (3175.6, 8741.7)	12	12 (100)	2512.9 (1493.5, 4228.1)
		18	19	19 (100)	3947.4 (2422.4, 6432.3)	12	12 (100)	1690.4 (1031.3, 2770.7)
		24	19	19 (100)	3150.7 (1939.1, 5119.5)	12	12 (100)	1261.4 (724.6, 2195.8)
		36	19	19 (100)	2857.9 (1750.4, 4665.9)	12	12 (100)	1007.9 (590.8, 1719.7)
		48	19	19 (100)	2413.0 (1472.3, 3954.7)	12	12 (100)	920.7 (558.6, 1517.6)
		60	19	19 (100)	2060.2 (1290.2, 3289.8)	12	12 (100)	831.2 (535.4, 1290.5)
	Total	0	146	19 (13.0)	5.1 (4.5, 5.9)	131	12 (9.2)	4.9 (4.3, 5.6)
		7	146	146 (100)	14420.7 (12115.7, 17164.2)	131	131 (100)	8482.5 (7302.4, 9853.3)
		12	145	145 (100)	5198.7 (4330.5, 6241.0)	131	131 (100)	2669.4, 2305.9, 3090.2)
		18	144	144 (100)	3486.4 (2919.0, 4164.1)	131	131 (100)	1813.7 (1563.5, 2104.0)
		24	144	144 (100)	2735.7 (2293.2, 3263.6)	130	130 (100)	1387.9 (1200.6, 1604.4)
36		146	146 (100)	2334.9 (1968.0, 2770.2)	128	128 (100)	1159.2 (998.6, 1345.8)	
48		141	141 (100)	1957.6 (1649.0, 2323.9)	130	130 (100)	994.5 (858.7, 1151.9)	
60		146	146 (100)	1858.5 (1586.2, 2177.6)	131	131 (100)	976.1 (846.1, 1126.1)	

Age (years)	Pre-vaccination status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
9–14	Seronegative	0	48	0 (0.0)	4.0 (4.0, 4.0)	45	0 (0.0)	4.0 (4.0, 4.0)
		7	48	48 (100)	22812.9 (17484.3, 29765.3)	45	45 (100)	12444.6 (9930.2, 15595.7)
		12	48	48 (100)	8012.7 (5851.2, 10972.7)	45	45 (100)	3717.7 (2990.1, 4622.4)
		18	48	48 (100)	5448.9 (4054.2, 7323.2)	45	45 (100)	2465.0 (1974.8, 3076.7)
		24	47	47 (100)	4171.2 (3059.3, 5687.2)	45	45 (100)	1857.9 (1500.6, 2300.2)
		36	48	48 (100)	3512.1 (2610.4, 4725.4)	43	43 (100)	1654.3 (1316.8, 2078.2)
		48	48	48 (100)	2814.0 (2095.5, 3778.8)	44	44 (100)	1374.1 (1111.6, 1698.7)
		60	48	48 (100)	2670.8 (2018.6, 3533.8)	45	45 (100)	1369.0 (1104.0, 1697.5)
	Seropositive	0	7	7 (100)	13.3 (9.5, 18.7)	1	1 (100)	9.0
		7	7	7 (100)	17621.9 (9057.5, 34284.6)	1	1 (100)	13949.0
		12	7	7 (100)	7441.0 (4508.7, 12280.4)	1	1 (100)	3434.0
		18	7	7 (100)	5065.8 (3441.4, 7456.8)	1	1 (100)	1877.0
		24	7	7 (100)	4256.5 (3030.9, 5977.6)	1	1 (100)	894.0
		36	7	7 (100)	3970.0 (2878.4, 5475.7)	1	1 (100)	981.0
		48	7	7 (100)	3032.3 (1775.5, 5178.6)	1	1 (100)	563.0
		60	7	7 (100)	2408.1 (1353.6, 4284.1)	1	1 (100)	512.0
	Total	0	55	7 (12.7)	4.7 (4.2, 5.2)	46	1 (2.2)	4.1 (3.9, 4.2)
		7	55	55 (100)	22075.4 (17345.5, 28095.1)	46	46 (100)	12475.5 (10005.2, 15555.8)
		12	55	55 (100)	7937.6 (6014.3, 10476.0)	46	46 (100)	3711.3 (2999.6, 4591.9)
		18	55	55 (100)	5398.5 (4164.1, 6998.9)	46	46 (100)	2450.4 (1972.4, 3044.3)
		24	54	54 (100)	4182.2 (3190.6, 5481.8)	46	46 (100)	1828.6 (1480.4, 2258.5)
36		55	55 (100)	3567.3 (2751.0, 4625.9)	44	44 (100)	1634.8 (1306.7, 2045.3)	
48		55	55 (100)	2840.9 (2187.4, 3689.6)	45	45 (100)	1347.2 (1090.9, 1663.5)	
60		55	55 (100)	2635.9 (2053.3, 3383.7)	46	46 (100)	1340.0 (1081.2, 1660.8)	
15–25	Seronegative	0	79	0 (0.0)	4.0 (4.0, 4.0)	74	0 (0.0)	4.0 (4.0, 4.0)
		7	79	79 (100)	11492.0 (9059.4, 14577.7)	74	74 (100)	7199.0 (5890.0, 8798.9)
		12	78	78 (100)	3970.6 (3116.5, 5058.7)	74	74 (100)	2203.9 (1802.3, 2694.9)
		18	77	77 (100)	2559.6 (2022.4, 3239.5)	74	74 (100)	1522.3 (1236.7, 1873.8)
		24	78	78 (100)	2050.0 (1630.7, 2576.9)	73	73 (100)	1177.8 (963.2, 1440.2)
		36	79	79 (100)	1735.5 (1393.4, 2161.7)	73	73 (100)	962.0 (787.0, 1176.0)
		48	74	74 (100)	1466.1 (1172.4, 1833.3)	74	74 (100)	830.9 (676.3, 1020.9)
		60	79	79 (100)	1454.5 (1187.2, 1782.1)	74	74 (100)	815.6 (669.3, 994.0)
	Seropositive	0	12	12 (100)	42.5 (17.0, 106.3)	11	11 (100)	43.4 (21.0, 89.7)

Age (years)	Pre-vaccination status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
		7	12	12 (100)	9130.3 (4151.9, 20078.1)	11	11 (100)	5096.3 (2986.9, 8695.3)
		12	12	12 (100)	4307.7 (1965.3, 9442.2)	11	11 (100)	2442.6 (1377.4, 4331.4)
		18	12	12 (100)	3412.8 (1558.7, 7472.6)	11	11 (100)	1674.4 (968.5, 2894.8)
		24	12	12 (100)	2643.7 (1215.7, 5749.2)	11	11 (100)	1301.5 (707.1, 2395.3)
		36	12	12 (100)	2359.2 (1078.5, 5161.0)	11	11 (100)	1010.4 (558.7, 1827.2)
		48	12	12 (100)	2112.0 (974.0, 4579.5)	11	11 (100)	962.8 (559.2, 1657.8)
		60	12	12 (100)	1881.0 (909.8, 3888.7)	11	11 (100)	868.7 (539.8, 1398.0)
	Total	0	91	12 (13.2)	5.5 (4.5, 6.7)	85	11 (12.9)	5.4 (4.5, 6.6)
		7	91	91 (100)	11148.6 (8898.8, 13967.2)	85	85 (100)	6884.3 (5717.7, 8288.8)
		12	90	90 (100)	4014.0 (3194.8, 5043.2)	85	85 (100)	2233.4 (1854.5, 2689.7)
		18	89	89 (100)	2660.9 (2127.0, 3328.8)	85	85 (100)	1541.2 (1274.0, 1864.3)
		24	90	90 (100)	2120.7 (1705.3, 2637.2)	84	84 (100)	1193.3 (989.5, 1439.2)
		36	91	91 (100)	1807.2 (1463.0, 2232.5)	84	84 (100)	968.2 (803.7, 1166.5)
		48	86	86 (100)	1542.7 (1244.0, 1913.2)	85	85 (100)	846.9 (701.2, 1023.0)
		60	91	91 (100)	1504.7 (1237.7, 1829.3)	85	85 (100)	822.3 (687.1, 984.1)

2D, two-dose schedule of the licensed HPV-16/18 AS04-adjuvanted vaccine formulation; 3D, three-dose schedule of the licensed HPV-16/18 AS04-adjuvanted vaccine formulation; 95% CI, exact 95% confidence interval; ATP-I, according-to-protocol immunogenicity cohort; ELISA, enzyme-linked immunosorbent assay; EU/mL, ELISA unit per milliliter; GMT, geometric mean antibody titer; M, month; N, number of evaluable seronegative subjects in the Month 60 according-to-protocol immunogenicity cohort; n (%), number (percentage) of seropositive subjects with antibody titer greater than or equal to the assay cut-off (titer equal to or above 8 EU/mL at Months 0, 7, 12, 18, 24, 36 and 48; titer equal to or above 19 EU/mL at Month 60). *Antibody titers below the assay cut-off were given an arbitrary value of half the cut-off for the purpose of GMT calculation.

Supp. Table 2 HPV-18 antibody responses up to Month 60 by age stratum and pre-vaccination serostatus (Month 60 ATP-I)

Age (years)	Pre-vacc status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
9–25	Seronegative	0	125	0 (0.0)	3.5 (3.5, 3.5)	116	0 (0.0)	3.5 (3.5, 3.5)
		7	125	125 (100)	5594.8 (4744.6, 6597.3)	116	116 (100)	5294.6 (4589.5, 6107.9)
		12	124	124 (100)	1897.1 (1559.9, 2307.3)	116	116 (100)	1514.6 (1269.5, 1807.0)
		18	123	123 (100)	1245.7 (1026.2, 1512.1)	116	116 (100)	926.8 (773.9, 1110.1)
		24	123	123 (100)	994.6 (818.0, 1209.4)	115	115 (100)	729.9 (609.8, 873.6)
		36	125	125 (100)	888.4 (730.3, 1080.7)	113	113 (100)	655.2 (541.5, 792.7)
		48	122	122 (100)	724.4 (594.5, 882.6)	115	115 (100)	544.7 (454.4, 652.9)
		60	125	125 (100)	730.7 (606.8, 879.8)	116	116 (100)	576.0 (481.1, 689.5)
	Seropositive	0	21	21 (100)	15.0 (10.8, 21.0)	15	15 (100)	15.6 (9.5, 25.5)
		7	21	21 (100)	4521.9 (2779.9, 7355.5)	15	15 (100)	6015.2 (4133.3, 8754.1)
		12	21	21 (100)	1697.3 (1015.6, 2836.7)	15	15 (100)	1611.7 (1012.3, 2566.1)
		18	21	21 (100)	1223.5 (738.7, 2026.4)	15	15 (100)	928.0 (584.9, 1472.5)
		24	21	21 (100)	932.3 (557.1, 1560.1)	15	15 (100)	735.7 (481.7, 1123.8)
		36	21	21 (100)	896.7 (530.9, 1514.5)	15	15 (100)	591.7 (386.1, 906.8)
		48	19	19 (100)	733.8 (415.4, 1296.0)	15	15 (100)	496.4 (339.2, 726.6)
		60	21	21 (100)	838.5 (542.3, 1296.4)	15	15 (100)	435.9 (309.8, 613.2)
	Total	0	146	21 (14.4)	4.3 (3.9, 4.7)	131	15 (11.5)	4.2 (3.8, 4.6)
		7	146	146 (100)	5426.0 (4644.3, 6339.3)	131	131 (100)	5372.5 (4707.1, 6132.0)
		12	145	145 (100)	1866.8 (1557.9, 2236.9)	131	131 (100)	1525.4 (1295.7, 1795.8)
		18	144	144 (100)	1242.4 (1039.1, 1485.6)	131	131 (100)	927.0 (784.9, 1094.7)
		24	144	144 (100)	985.3 (822.4, 1180.4)	130	130 (100)	730.5 (619.6, 861.3)
36		146	146 (100)	889.6 (742.0, 1066.5)	128	128 (100)	647.4 (544.1, 770.3)	
48		141	141 (100)	725.6 (603.3, 872.8)	130	130 (100)	538.9 (457.0, 635.5)	
60		146	146 (100)	745.3 (629.3, 882.7)	131	131 (100)	557.9 (473.7, 657.0)	

Age (years)	Pre-vacc status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
9–14	Seronegative	0	49	0 (0.0)	3.5 (3.5, 3.5)	43	0 (0.0)	3.5 (3.5, 3.5)
		7	49	49 (100)	7811.4 (6105.4, 9994.2)	43	43 (100)	5880.7 (4721.3, 7324.8)
		12	49	49 (100)	2622.7 (1916.1, 3589.9)	43	43 (100)	1693.8 (1271.5, 2256.4)
		18	49	49 (100)	1651.3 (1235.0, 2207.9)	43	43 (100)	976.1 (724.3, 1315.5)
		24	48	48 (100)	1353.3 (1004.1, 1824.2)	43	43 (100)	745.2 (554.2, 1002.1)
		36	49	49 (100)	1197.7 (901.5, 1591.1)	41	41 (100)	705.4 (516.3, 963.8)
		48	49	49 (100)	962.6 (718.7, 1289.1)	42	42 (100)	566.6 (428.0, 749.9)
		60	49	49 (100)	908.9 (682.3, 1210.7)	43	43 (100)	627.2 (476.1, 826.1)
	Seropositive	0	6	6 (100)	15.9 (7.6, 3.6)	3	3 (100)	8.0 (5.8, 10.9)
		7	6	6 (100)	6112.6 (3530.0, 10584.4)	3	3 (100)	8010.4 (2256.9, 28431.7)
		12	6	6 (100)	2149.9 (1183.2, 3906.5)	3	3 (100)	2115.0 (502.1, 8908.4)
		18	6	6 (100)	1519.1 (787.4, 2930.4)	3	3 (100)	1075.2 (277.2, 4169.8)
		24	6	6 (100)	1206.3 (635.7, 2289.1)	3	3 (100)	909.5 (327.0, 2529.1)
		36	6	6 (100)	1207.2 (641.8, 2270.5)	3	3 (100)	686.4 (188.7, 2497.3)
		48	6	6 (100)	864.1 (440.1, 1696.5)	3	3 (100)	597.2 (314.0, 1135.5)
		60	6	6 (100)	959.2 (517.0, 1779.9)	3	3 (100)	559.7 (269.2, 1163.5)
	Total	0	55	6 (10.9)	4.1 (3.6, 4.8)	46	3 (6.5)	3.7 (3.5, 3.9)
		7	55	55 (100)	7605.2 (6080.0, 9513.0)	46	46 (100)	6000.4 (4871.4, 7391.1)
		12	55	55 (100)	2566.5 (1934.0, 3405.8)	46	46 (100)	1718.5 (1311.5, 2251.8)
		18	55	55 (100)	1636.3 (1258.0, 2128.4)	46	46 (100)	982.3 (742.1, 1300.2)
		24	54	54 (100)	1336.2 (1020.6, 1749.2)	46	46 (100)	754.9 (571.9, 996.6)
		36	55	55 (100)	1198.7 (927.2, 1549.7)	44	44 (100)	704.1 (525.8, 942.8)
		48	55	55 (100)	951.3 (730.1, 1239.5)	45	45 (100)	568.6 (437.7, 738.5)
		60	55	55 (100)	914.2 (705.6, 1184.6)	46	46 (100)	622.5 (481.1, 805.5)
15–25	Seronegative	0	76	0 (0.0)	3.5 (3.5, 3.5)	73	0 (0.0)	3.5 (3.5, 3.5)
		7	76	76 (100)	4511.6 (3658.0, 5564.4)	73	73 (100)	4977.0 (4119.5, 6013.1)
		12	75	75 (100)	1535.3 (1202.7, 1959.9)	73	73 (100)	1418.0 (1129.2, 1780.7)
		18	74	74 (100)	1033.6 (801.1, 1333.5)	73	73 (100)	899.0 (713.1, 1133.3)
		24	75	75 (100)	816.7 (634.4, 1051.4)	72	72 (100)	720.9 (571.8, 908.9)
		36	76	76 (100)	732.7 (564.5, 951.2)	72	72 (100)	628.2 (491.4, 803.1)
		48	73	73 (100)	598.5 (460.5, 777.8)	73	73 (100)	532.5 (418.7, 677.2)
		60	76	76 (100)	634.8 (497.9, 809.3)	73	73 (100)	547.8 (431.1, 696.0)
	Seropositive	0	15	15 (100)	14.7 (9.6, 22.4)	12	12 (100)	18.4 (10.2, 33.0)

Age (years)	Pre-vacc status	Month	3D M0,1,6 schedule			2D M0,6 schedule		
			N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
		7	15	15 (100)	4008.4 (2043.7, 7861.7)	12	12 (100)	5599.5 (3558.6, 8811.1)
		12	15	15 (100)	1544.2 (755.0, 3158.3)	12	12 (100)	1505.9 (849.6, 2669.1)
		18	15	15 (100)	1122.1 (558.5, 2254.3)	12	12 (100)	894.5 (502.7, 1591.8)
		24	15	15 (100)	841.0 (412.4, 1714.7)	12	12 (100)	697.8 (410.3, 1186.7)
		36	15	15 (100)	796.1 (385.8, 1642.9)	12	12 (100)	570.1 (335.1, 970.1)
		48	13	13 (100)	680.4 (296.0, 1564.3)	12	12 (100)	474.0 (292.4, 768.5)
		60	15	15 (100)	794.5 (436.0, 1447.9)	12	12 (100)	409.5 (267.8, 626.0)
	Total	0	91	15 (16.5)	4.4 (3.9, 5.0)	85	12 (14.1)	4.4 (3.8, 5.1)
		7	91	91 (100)	4424.5 (3617.8, 5411.0)	85	85 (100)	5060.5 (4263.5, 6006.6)
		12	90	90 (100)	1536.8 (1221.9, 1932.9)	85	85 (100)	1430.1 (1162.3, 1759.5)
		18	89	89 (100)	1048.0 (827.6, 1327.1)	85	85 (100)	898.3 (727.8, 1108.9)
		24	90	90 (100)	820.7 (648.6, 1038.5)	84	84 (100)	717.5 (582.4, 884.0)
		36	91	91 (100)	742.8 (583.0, 946.5)	84	84 (100)	619.5 (497.2, 772.1)
		48	86	86 (100)	610.2 (476.2, 782.0)	85	85 (100)	523.8 (422.7, 649.1)
		60	91	91 (100)	658.7 (527.8, 822.1)	85	85 (100)	525.7 (425.0, 650.3)

2D, two-dose schedule of the licensed HPV-16/18 AS04-adjuvanted vaccine formulation; 3D, three-dose schedule of the licensed HPV-16/18 AS04-adjuvanted vaccine formulation; 95% CI, exact 95% confidence interval; ATP-I, according-to-protocol immunogenicity cohort; ELISA, enzyme-linked immunosorbent assay; EU/mL, ELISA unit per milliliter; GMT, geometric mean antibody titer; M, month; N, number of evaluable seronegative subjects in the Month 60 according-to-protocol immunogenicity cohort; n (%), number (percentage) of seropositive subjects with antibody titer greater than or equal to the assay cut-off (titer equal to or above 7 EU/mL at Months 0, 7, 12, 18, 24, 36 and 48; titer equal to or above 18 EU/mL at Month 60). *Antibody titers below the assay cut-off were given an arbitrary value of half the cut-off for the purpose of GMT calculation.